NCT03355300 - Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 20, 2018

Primary Completion Date

June 24, 2019

Study Completion Date

June 28, 2019

Conditions

Childhood Absence Epilepsy

Interventions

DRUG

Cannabidiol Oral Solution

An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).

Trial Locations (9)

Children's Hospital of Philadelphia, Philadelphia

Children's Specialty Group, Division of Child & Adolescent Neurology, Norfolk

Clinical Integrative Research Center of Atlanta, Atlanta

Nicklaus Children's Hospital, Miami

Pediatric Epilepsy and Neurology Specialists, Tampa

Akron Children's Hospital, Akron

Primary Children's Hospital, Salt Lake City

Oregon Health and Science University, Portland

"Institute for Research and Innovation , MultiCare Health System"